Artificial intelligence for early detection of pancreatic adenocarcinoma: The future is promising.

Antonio Mendoza Ladd, David L Diehl

Journal: World journal of gastroenterology 2021;27(13):1283-1295

PMID: 33833482

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a worldwide public health concern. Despite extensive research efforts toward improving diagnosis and treatment, the 5-year survival rate at best is approximately 15%. This dismal figure can be attributed to a variety of factors including lack of adequate screening methods, late symptom onset, and treatment resistance. Pancreatic ductal adenocarcinoma remains a grim diagnosis with a high mortality rate and a significant psy-chological burden for patients and their families. In recent years artificial intelligence (AI) has permeated the medical field at an accelerated pace, bringing potential new tools that carry the promise of improving diagnosis and treatment of a variety of diseases. In this review we will summarize the landscape of AI in diagnosis and treatment of PDAC.

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Address: Department of Internal Medicine, Division of Gastroenterology, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, United States. [email protected].; Department of Gastroenterology and Nutrition, Geisinger Medical Center, Danville, PA 17822, United States.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.